Peer-influenced content. Sources you trust. No registration required. This is HCN.

Features:
CME JOBS OUTBREAKS PEER-TO-PEER QUIZZES & QUESTIONS MEDTECH

The New England Journal of MedicineRucaparib or Physician’s Choice in Metastatic Prostate Cancer

An inhibitor of poly(ADP-ribose) polymerase (PARP), rucaparib, demonstrated high levels of efficacy in patients with metastatic, castration-resistant prostate cancer coupled with a harmful BRCA change in a phase 2 research. To support and add to the findings of the phase 2 trial, data are required.

Was this Essential useful?

More Essentials From

ACP Internist
Annals of Internal Medicine
British Medical Journal
Cancer Therapy Advisor
Cleveland Clinic Journal of Medicine
Clinical Advisor
Consultant360
Dana-Farber Cancer Institute
Healthgrades for Professionals
MDLinx
Neurology Advisor
OBR Oncology
Oncology Learning Network
Psych Congress Network
Psychiatrist.com
The Epoch Times
The New England Journal of Medicine
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form